Acarbose for the prevention of diabetes, hypertension, and cardiovascular disease in subjects with impaired glucose tolerance: The Study to Prevent Non-Insulin-Dependent Diabetes Mellitus (STOP-NIDDM) Trial

Endocrine Practice

Volumn 12, Issue SUPPL. 1, 2006, Pages 25-30

  Chiasson, Jean Louis ^a  

^a CENTRE HOSPITALIER DE L UNIVERSITÉ DE MONTRÉAL   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ACARBOSE; PLACEBO; ANTIDIABETIC AGENT;

CARDIOVASCULAR DISEASE; CLINICAL TRIAL; CONFERENCE PAPER; CONFIDENCE INTERVAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; DOUBLE BLIND PROCEDURE; DRUG WITHDRAWAL; FOLLOW UP; HUMAN; HYPERTENSION; IMPAIRED GLUCOSE TOLERANCE; INCIDENCE; ISCHEMIC HEART DISEASE; MAJOR CLINICAL STUDY; MULTICENTER STUDY; NON INSULIN DEPENDENT DIABETES MELLITUS; ORAL GLUCOSE TOLERANCE TEST; OUTCOME ASSESSMENT; PERIPHERAL VASCULAR DISEASE; RANDOMIZED CONTROLLED TRIAL; RISK ASSESSMENT; RISK REDUCTION; STROKE; SWEDEN; COST BENEFIT ANALYSIS; ECONOMICS; GLUCOSE INTOLERANCE; GLUCOSE TOLERANCE TEST; INSULIN RESISTANCE; REVIEW;

ACARBOSE; CARDIOVASCULAR DISEASES; COST-BENEFIT ANALYSIS; DIABETES MELLITUS, TYPE 2; DOUBLE-BLIND METHOD; GLUCOSE INTOLERANCE; GLUCOSE TOLERANCE TEST; HUMANS; HYPERTENSION; HYPOGLYCEMIC AGENTS; INSULIN RESISTANCE; MULTICENTER STUDIES; PLACEBOS; RANDOMIZED CONTROLLED TRIALS;

EID: 33646574976     PISSN: 1530891X     EISSN: None     Source Type: Journal    
DOI: 10.4158/ep.12.s1.25     Document Type: Conference Paper

References (29)

1. Wild S, Roglic G, Green A, Sicree R, King H. Global prevalence of diabetes: estimates for the year 2000 and projections for 2030. Diabetes Care. 2004;27:1047-1053.
2. Jonsson B. The economic impact of diabetes. Diabetes Care. 1998;21(Suppl 3):C7-C10.
3. Skyler JS, Oddo C. Diabetes trends in the USA. Diabetes Metab Res Rev. 2002;18(Suppl 3):S21-S26.
4. Zimmet P, Alberti KG, Shaw J. Global and societal implications of the diabetes epidemic. Nature. 2001;414: 782-787.
5. Kahn SE. The relative contributions of insulin resistance and beta-cell dysfunction to the pathophysiology of type 2 diabetes. Diabetologia. 2003;46:3-19.
6. Ferrannini E, Gastaldelli A, Miyazaki Y, et al. Predominant role of reduced beta-cell sensitivity to glucose over insulin resistance in impaired glucose tolerance. Diabetologia. 2003;46:1211-1219.
7. Leahy JL, Bonner-Weir S, Weir GC. Beta-cell dysfunction induced by chronic hyperglycemia: current ideas on mechanism of impaired glucose-induced insulin secretion 3. Diabetes Care. 1992;15:442-455.
8. Rossetti L. Glucose toxicity: the implications of hyperglycemia in the pathophysiology of diabetes mellitus. Clin Invest Med. 1995;18:255-260.
9. Saad MF, Knowler WC, Pettitt DJ, Nelson RG, Mott DM, Bennett PH. The natural history of impaired glucose tolerance in the Pima Indians. N Engl J Med. 1988;319: 1500-1506.
10. Harris MI. Impaired glucose tolerance - prevalence and conversion to NIDDM. Diabet Med. 1996;13(3 Suppl 2): S9-S11.
11. Heine RJ, Nijpels G, Mooy JM. New data on the rate of progression of impaired glucose tolerance to NIDDM and predicting factors. Diabet Med. 1996;13(3 Suppl 2):S12-S14.
12. Haffner SM, Lehto S, Rönnemaa T, Pyörälä K, Laakso M. Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction. N Engl J Med. 1998;339: 229-234.
13. Manson JE, Colditz GA, Stampfer MJ, et al. A prospective study of maturity-onset diabetes mellitus and risk of coronary heart disease and stroke in women. Arch Intern Med. 1991;151:1141-1147.
14. Haffner S, Cassells HB. Metabolic syndrome - a new risk factor of coronary heart disease? Diabetes Obes Metab. 2003;5:359-370.
15. Wei M, Gaskill SP, Haffner SM, Stern MP. Effects of diabetes and level of glycemia on all-cause and cardiovascular mortality: the San Antonio Heart Study. Diabetes Care. 1998;21:1167-1172.
16. Haffner SM, Cassells H. Hyperglycemia as a cardiovascular risk factor. Am J Med. 2003;115(Suppl 8A):6S-11S.
17. Patane G, Piro S, Rabuazzo AM, Anello M, Vigneri R, Purrello F. Metformin restores insulin secretion altered by chronic exposure to free fatty acids or high glucose: a direct metformin effect on pancreatic beta-cells. Diabetes. 2000;49:735-740.
18. Donahue RP, Abbott RD, Reed DM, Yano K. Post-challenge glucose concentration and coronary heart disease in men of Japanese ancestry: Honolulu Heart Program. Diabetes. 1987;36:689-692.
19. Fontbonne A, Eschwège E, Cambien F, et al. Hypertriglyceridaemia as a risk factor of coronary heart disease mortality in subjects with impaired glucose tolerance or diabetes: results from the 11-year follow-up of the Paris Prospective Study. Diabetologia. 1989;32:300-304.
20. Tominaga M, Eguchi H, Manaka H, Igarashi K, Kato T, Sekikawa A. Impaired glucose tolerance is a risk factor for cardiovascular disease, but not impaired fasting glucose: the Funagata Diabetes Study. Diabetes Care. 1999; 22:920-924.
21. Barzilay JI, Spiekerman CF, Wahl PW, et al. Cardiovascular disease in older adults with glucose disorders: comparison of American Diabetes Association criteria for diabetes mellitus with WHO criteria. Lancet. 1999;354: 622-625.
22. Diabetes Epidemiology: Collaborative Analysis of Diagnostic Criteria in Europe (DECODE) Study Group and the European Diabetes Epidemiology Group. Glucose tolerance and mortality: comparison of WHO and American Diabetes Association diagnostic criteria. Lancet. 1999;354:617-621.
23. Hu FB, Stampfer MJ, Haffner SM, Solomon CG, Willett WC, Manson JE. Elevated risk of cardiovascular disease prior to clinical diagnosis of type 2 diabetes. Diabetes Care. 2002;25:1129-1134.
24. Eschwege E, Richard JL, Thibult N, et al. Coronary heart disease mortality in relation with diabetes, blood glucose and plasma insulin levels: the Paris Prospective Study, ten years later. Horm Metab Res Suppl. 1985;15:41-46.
25. Chiasson JL, Gomis R, Hanefeld M, Josse RG, Karasik A, Laakso M. The STOP-NIDDM Trial: an international study on the efficacy of an alpha-glucosidase inhibitor to prevent type 2 diabetes in a population with impaired glucose tolerance; rationale, design, and preliminary screening data; Study to Prevent Non-Insulin-Dependent Diabetes Mellitus. Diabetes Care. 1998;21:1720-1725.
26. Chiasson JL, Josse RG, Gomis R, Hanefeld M, Karasik A, Laakso M (STOP-NIDDM Trial Research Group). Acarbose for prevention of type 2 diabetes mellitus: the STOP-NIDDM randomised trial. Lancet. 2002;359:2072-2077.
27. Chiasson JL, Josse RG, Gomis R, Hanefeld M, Karasik A, Laakso M (STOP-NIDDM Trial Research Group). Acarbose treatment and the risk of cardiovascular disease and hypertension in patients with impaired glucose tolerance: the STOP-NIDDM Trial. JAMA. 2003;290:486-494.
28. Stern MP, Williams K, Haffner SM. Identification of persons at high risk for type 2 diabetes mellitus: do we need the oral glucose tolerance test? Ann Intern Med. 2002; 136:575-581.
29. Anderson KM, Odell PM, Wilson PW, Kannel WB. Cardiovascular disease risk profiles. Am Heart J. 1991; 121(1 Pt 2):293-298.